Recent studies suggest that acetaminophen may be linked to poorer long-term outcomes in patients receiving immune checkpoint inhibitors. Since acetaminophen is a widely used and essential medication for many patients with cancer, it is important to ca…
Type 2 conventional dendritic cell (cDC2) gene signature was shown to be associated with better overall survival in patients with lung cancer and a fraction of patients with breast carcinoma, indicating that they may possess antitumoral function. Neve…
Type 2 conventional dendritic cell (cDC2) gene signature was shown to be associated with better overall survival in patients with lung cancer and a fraction of patients with breast carcinoma, indicating that they may possess antitumoral function. Neve…
Targeted resistance to immune checkpoint therapy remains a clinical challenge, and a recent study reported by Xie et al provides novel insights into how RNA acetylation, particularly N4-acetylcytidine (ac4C), plays a pivotal role in shaping the tumor …
Recent years have seen renewed appreciation of the critical role played by the prototypic T cell co-stimulatory receptor CD28 in cancer immunotherapy. Inhibition of co-stimulation by direct competition, as exemplified by cytotoxic T-lymphocyte associa…
First clinical trials demonstrated the safety of adoptive cell transfer with allogeneic natural killer (NK) cell products from healthy donors, making them an attractive candidate for ‘off-the-shelf’ chimeric antigen receptor (CAR)-immune c…
The incidence of cancer globally is increasing, predominantly because of an aging population and bringing with it substantial challenges. Cancer vaccines are based on the premise that there are unique features of a cancer or agents causing a cancer wh…
Prostate cancer (PC) is notoriously known for exhibiting an immunologically cold phenotype in the tumor immune microenvironment (TIME), leading to the need for interventions to enhance immunotherapy efficacy. Recent findings by Zhao et al. in the Jour…
Neoadjuvant immunochemotherapy (nICT) has demonstrated significant potential in improving pathological response rates and survival outcomes for patients with locally advanced esophageal squamous cell carcinoma (ESCC). However, substantial interindivid…
The recent phase 3 trial of the Fc-silent anti-programmed cell death protein-1 (PD-1) antibody finotonlimab demonstrated promising clinical activity in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). However, an unexpected finding …
